Cardiff Oncology Inc. (CRDF)

Number of Patients with a Complete Response Increases in AML Study

October 1, 2019
Report ID: 11109
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ā€˜Get Reportā€™ button to login and view the research report.

Not a Member? Click ā€˜Joinā€™ or ā€˜Get Reportā€™ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

ā€Œ
Cardiff Oncology Inc.
Cardiff Oncology Inc.
Healthcare
Biotechnology
Ticker
CRDF
Current Price
$5.505 2.13%
Market Cap
$245.9M
Price Target
Refer to Report
Volume
496.5K
52wk Range
$0.94 - $6.42
Related Research Reports
5/29/2020
ā€Œ
Lead Drug Gets Fast Track Designation by FDA
Lead Drug Gets Fast Track Designation by FDA (CRDF)
5/8/2020
ā€Œ
New CEO, New Name, Still a Promising Cancer Drug
New CEO, New Name, Still a Promising Cancer Drug (CRDF)
4/29/2020
ā€Œ
Lead Drug Shows Potential as KRAS inhibitor in Colorectal Cancer
Lead Drug Shows Potential as KRAS inhibitor in Colorectal Cancer (CRDF)
2/14/2020
ā€Œ
Lead Drug Shows Efficacy in Difficult to Treat Prostate Cancer Patients
Lead Drug Shows Efficacy in Difficult to Treat Prostate Cancer Patients (CRDF)

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
Ā© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.